ArticleNature cancer2026

The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations.

Johnny X Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.